Loading clinical trials...
Loading clinical trials...
A Phase 2, Randomized, Double Blind, Controlled Study to Evaluate the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis
Conditions
Interventions
VX-152
TEZ/IVA
+3 more
Locations
16
United States
Birmingham, Alabama, United States
La Jolla, California, United States
Los Angeles, California, United States
Orlando, Florida, United States
Chicago, Illinois, United States
Peoria, Illinois, United States
Start Date
November 1, 2016
Primary Completion Date
January 1, 2018
Completion Date
January 1, 2018
Last Updated
January 28, 2021
NCT04469439
NCT04530383
NCT06154447
NCT05422222
NCT06984679
NCT02417740
Lead Sponsor
Vertex Pharmaceuticals Incorporated
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions